摘要
目的探讨增强型体外反搏(EECP)联合沙库巴曲缬沙坦(SV)在老年慢性心力衰竭(CHF)患者中的应用及对心功能的影响。方法选取2020年2月至2021年8月于西安市第九医院住院治疗的CHF患者80例为研究对象,所有患者均进行EECP联合SV治疗,在治疗前1 d和治疗后3个月,收集血流动力学参数、心肌酶谱和动态心电检测系统对心功能充分评估。结果EECP联合SV治疗3个月后6 min步行距离(6MHWD)长于治疗前(P<0.05),MLHFQ评分少于治疗前(P<0.05),心脏指数、每搏量、心脏等容舒张期均大于治疗前(P<0.05),总外周阻力、平均动脉压均小于治疗前(P<0.05),脑钠肽(BNP)水平低于治疗前(P<0.05),而心肌酶谱水平和治疗前对比,差异不具有统计学意义(P>0.05),SDNN、SDNANN、RMSSD、心率变异性三角指数均高于治疗前(P<0.05)。结论EECP联合SV治疗可缩短老年CHF患者的6MHWD,降低MLHFQ评分,可改善其血流动力学,降低BNP,改善心率变异性时域定量各指标。
Objective To investigate the application of enhanced external counterpulsation(EECP)combined with Sacubitril/Valsartan(SV)in elderly patients with chronic heart failure(CHF)and its effect on cardiac function.Methods A total of 80 CHF patients hospitalized in our hospital from February 2020 to August 2021 were selected as the study objects.All patients were treated with EECP combined with SV and collected data 1 day before treatment and three months after treatment.Hemodynamic parameters,myocardial enzyme spectrum,and Holter monitoring system were collected to evaluate cardiac function fully.Results After three months of EECP combined with SV treatment,6MHWD was longer than before treatment(P<0.05),MLHFQ score was lower than before treatment(P<0.05),heart index,stroke volume,and isovolumic diastolic period were all longer than before treatment(P<0.05),total peripheral resistance and mean arterial pressure were lower than before treatment(P<0.05),BNP level was lower than before treatment(P<0.05),and the myocardial enzyme profile level was not statistically significant(P>0.05).SDNN,SDNANN,RMSSD,and triangle index of heart rate variability were all higher than before treatment(P<0.05).Conclusion EECP combined with SV therapy can shorten 6MHWD,reduce MLHFQ score,improve hemodynamics,reduce BNP,and improve time domain quantitative indicators of heart rate variability in elderly CHF patients.
作者
黄馨谅
张盼
屈璇
陈雅宁
崔莹雪
Huang Xinliang;Zhang Pan;Qu Xuan;Chen Yaning;Cui Yingxue(Department of Geriatrics,Xi'an Ninth Hospital,Xi'an,Shaanxi 710054,China;不详)
出处
《中国循证心血管医学杂志》
2022年第8期1001-1003,1011,共4页
Chinese Journal of Evidence-Based Cardiovascular Medicine
